肝癌新型患者来源临床前模型
本文综述了肝癌临床前模型的最新进展,指出基于细胞系和小鼠的传统模型未能充分预测临床疗效。患者来源的3D细胞培养和患者来源异种移植(PDX)模型,尤其人源化小鼠模型,能更好地模拟肝癌复杂性,但各有局限。强调临床医生与研究人员双向沟通对建立可靠模型系统的重要性。
要点
- 患者来源3D培养可助个性化治疗,但无法重现肿瘤微环境与免疫互作。
- 人源化PDX更忠实模拟肝癌生理,但成本高、耗时长,限制个体化应用。
- 临床与科研双向沟通是建立可靠模型并正确应用的关键。
核心结论
- 患者来源的3D细胞培养和PDX模型是提高肝癌临床前研究预测效度的新方向,但需权衡其局限。
研究设计与样本
- 综述,讨论肝癌临床前模型的最新进展,未报告系统检索范围或样本量。
主要发现
- 基于细胞系和小鼠的传统模型已促成成功转化,但多数临床试验失败,提示需改进临床前研究。
- 患者来源3D细胞培养可生成更特异和个性化的疗法,但无法重现肿瘤微环境和免疫系统互作。
- 患者来源异种移植尤其人源化小鼠模型更忠实模拟人肝癌生理,但成本高且耗时。
临床怎么用
- 临床医生与研究人员应建立双向沟通,以建立可靠模型系统并确定其最佳应用方式。
局限性
- 3D培养系统无法重现肿瘤微环境和免疫系统互作。
- 人源化PDX模型成本高、耗时长,可能限制在侵袭性肝癌中个性化治疗的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preclinical models of cancer based on the use of human cancer cell lines and mouse models have enabled discoveries that have been successfully translated into patients. And yet the majority of clinical trials fail, emphasising the urgent need to improve preclinical research to better interrogate the potential efficacy of each therapy and the patient population most likely to benefit. This is particularly important for liver malignancies, which lack highly efficient treatments and account for hundreds of thousands of deaths around the globe. Given the intricate network of genetic and environmental factors that contribute to liver cancer development and progression, the identification of new druggable targets will mainly depend on establishing preclinical models that mirror the complexity of features observed in patients. The development of new 3D cell culture systems, originating from cells/tissues isolated from patients, might create new opportunities for the generation of more specific and personalised therapies. However, these systems are unable to recapitulate the tumour microenvironment and interactions with the immune system, both proven to be critical influences on therapeutic outcomes. Patient-derived xenografts, in particular with humanised mouse models, more faithfully mimic the physiology of human liver cancer but are costly and time-consuming, which can be prohibitive for personalising therapies in the setting of an aggressive malignancy. In this review, we discuss the latest advances in the development of more accurate preclinical models to better understand liver cancer biology and identify paradigm-changing therapies, stressing the importance of a bi-directional communicative flow between clinicians and researchers to establish reliable model systems and determine how best to apply them to expanding our current knowledge.
引用
- Bresnahan E, Ramadori P, Heikenwalder M, et al. Novel patient-derived preclinical models of liver cancer. J Hepatol. 2020. PMID: 31954489. doi:10.1016/j.jhep.2019.09.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。